Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 287 articles:
HTML format



Single Articles


    November 2022
  1. LIU Y, Shi J, Li L, Wu T, et al
    Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Nov 30:e0053122. doi: 10.1128/aac.00531.
    PubMed     Abstract available


  2. WONG CF, Saw WG, Basak S, Sano M, et al
    Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors.
    Antimicrob Agents Chemother. 2022 Nov 29:e0105622. doi: 10.1128/aac.01056.
    PubMed     Abstract available


  3. YU XH, Hao ZH, Liu PL, Liu MM, et al
    Increased Expression of Efflux Pump norA Drives the Rapid Evolutionary Trajectory from Tolerance to Resistance against Ciprofloxacin in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2022 Nov 29:e0059422. doi: 10.1128/aac.00594.
    PubMed     Abstract available


  4. HULL RC, Wright RCT, Sayers JR, Sutton JAF, et al
    Antibiotics Limit Adaptation of Drug-Resistant Staphylococcus aureus to Hypoxia.
    Antimicrob Agents Chemother. 2022 Nov 21:e0092622. doi: 10.1128/aac.00926.
    PubMed     Abstract available


  5. MANSJO M, Karlsson Lindsjo O, Gronfors Seeth C, Groenheit R, et al
    The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Nov 21:e0102622. doi: 10.1128/aac.01026.
    PubMed     Abstract available


  6. LYONS MA
    Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
    Antimicrob Agents Chemother. 2022 Nov 15:e0089822. doi: 10.1128/aac.00898.
    PubMed     Abstract available


  7. NELSON M, Burton N, Nunez A, Butcher W, et al
    Efficacy of Co-Trimoxazole against Experimental Melioidosis Acquired by Different Routes of Infection.
    Antimicrob Agents Chemother. 2022;66:e0070822.
    PubMed     Abstract available


  8. MCCOLLAM S, Lewis JS 2nd, Bubalo J, Diaz A, et al
    Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.
    Antimicrob Agents Chemother. 2022;66:e0083322.
    PubMed     Abstract available


  9. WINTERS CG, Basnet RM, Faasuamalie PE, Shallom SJ, et al
    Disulfiram Is Effective against Drug-Resistant Mycobacterium abscessus in a Zebrafish Embryo Infection Model.
    Antimicrob Agents Chemother. 2022;66:e0053922.
    PubMed     Abstract available


  10. SAH SK, Bhattacharya S, Yadav A, Husain F, et al
    Multiple Genes of Candida albicans Influencing Echinocandin Susceptibility in Caspofungin-Adapted Mutants.
    Antimicrob Agents Chemother. 2022 Nov 10:e0097722. doi: 10.1128/aac.00977.
    PubMed     Abstract available


  11. YEO HH, Shiau CW, Jao YH, Wan TW, et al
    Rapid Bactericidal Activity of SC5005 Combined with Docosahexaenoic Acid against Multidrug-Resistant Staphylococcus aureus Persisters and Biofilms.
    Antimicrob Agents Chemother. 2022 Nov 10:e0080322. doi: 10.1128/aac.00803.
    PubMed     Abstract available


  12. SARATHY JP, Zimmerman MD, Gengenbacher M, Dartois V, et al
    Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro.
    Antimicrob Agents Chemother. 2022 Nov 9:e0123722. doi: 10.1128/aac.01237.
    PubMed     Abstract available


  13. DEVENTER AT, Bryson D, Shortill M, Boraston AB, et al
    Molecular Characterization of Clinical Rel Mutations and Consequences for Resistance Expression and Fitness in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2022 Nov 8:e0093822. doi: 10.1128/aac.00938.
    PubMed     Abstract available


  14. MON AS, Ei PW, Htwe MM, Nyunt MH, et al
    First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar.
    Antimicrob Agents Chemother. 2022 Nov 7:e0092522. doi: 10.1128/aac.00925.
    PubMed    


  15. CABELLOS C, Guillem L, Pelegrin I, Tubau F, et al
    Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis: Treatment in the Real World and in Guidelines.
    Antimicrob Agents Chemother. 2022 Nov 3:e0082022. doi: 10.1128/aac.00820.
    PubMed     Abstract available


  16. NGUYEN TQ, Hanh BTB, Jeon S, Heo BE, et al
    Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Nov 2:e0044822. doi: 10.1128/aac.00448.
    PubMed     Abstract available


    October 2022
  17. AN L, Tan J, Wang Y, Liu S, et al
    Synergistic Effect of the Combination of Deferoxamine and Fluconazole In Vitro and In Vivo against Fluconazole-Resistant Candida Spp.
    Antimicrob Agents Chemother. 2022 Oct 26:e0072522. doi: 10.1128/aac.00725.
    PubMed     Abstract available


  18. SINGH KV, Montealegre MC, Murray BE
    Enterococcus faecium Clade Competition in the Presence of beta-Lactam Antibiotics in a Mouse GI Tract Colonization Model.
    Antimicrob Agents Chemother. 2022 Oct 18:e0090322. doi: 10.1128/aac.00903.
    PubMed     Abstract available


  19. MCNEIL JC, Sommer LM, Vallejo JG, Hulten KG, et al
    Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.
    Antimicrob Agents Chemother. 2022;66:e0074522.
    PubMed     Abstract available


  20. KIM SR, Jang M, Kim SY, Kim DH, et al
    Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease.
    Antimicrob Agents Chemother. 2022;66:e0077422.
    PubMed     Abstract available


  21. PETRAITIS V, Petraitiene R, Kavaliauskas P, Naing E, et al
    Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
    Antimicrob Agents Chemother. 2022;66:e0061822.
    PubMed     Abstract available


  22. PHIPPS AJ, Bergmann JN, Albrecht MT, Singh VK, et al
    Model for Evaluating Antimicrobial Therapy To Prevent Life-Threatening Bacterial Infections following Exposure to a Medically Significant Radiation Dose.
    Antimicrob Agents Chemother. 2022;66:e0054622.
    PubMed     Abstract available


  23. AL-ZUBAIDI A, Cheung CY, Cook GM, Taiaroa G, et al
    RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
    Antimicrob Agents Chemother. 2022;66:e0209121.
    PubMed     Abstract available


  24. FINDLAY J, Rens C, Poirel L, Nordmann P, et al
    In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2022;66:e0091822.
    PubMed     Abstract available


  25. PINCUS NB, Rosas-Lemus M, Gatesy SWM, Bertucci HK, et al
    Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family beta-Lactamase from Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2022;66:e0098522.
    PubMed     Abstract available


  26. MON KKZ, Si Z, Chan-Park MB, Kenney LJ, et al
    Polyimidazolium Protects against an Invasive Clinical Isolate of Salmonella Typhimurium.
    Antimicrob Agents Chemother. 2022;66:e0059722.
    PubMed     Abstract available


  27. KUNZ COYNE AJ, Alshaer M, Casapao AM, Venugopalan V, et al
    Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.
    Antimicrob Agents Chemother. 2022;66:e0064622.
    PubMed     Abstract available


  28. KIM TY, Huh HJ, Lee GY, Choi MJ, et al
    Evolution of Fluconazole Resistance Mechanisms and Clonal Types of Candida parapsilosis Isolates from a Tertiary Care Hospital in South Korea.
    Antimicrob Agents Chemother. 2022 Oct 13:e0088922. doi: 10.1128/aac.00889.
    PubMed     Abstract available


  29. HISATSUNE J, Tanimoto K, Kohara T, Myoken Y, et al
    First Isolation of Vancomycin-Resistant Enterococcus faecium Carrying Plasmid-Borne vanD1.
    Antimicrob Agents Chemother. 2022 Oct 12:e0102922. doi: 10.1128/aac.01029.
    PubMed     Abstract available


  30. PLAUNT AJ, Rose SJ, Kang JY, Chen KJ, et al
    Correction for Plaunt et al., "Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections".
    Antimicrob Agents Chemother. 2022 Oct 12:e0125622. doi: 10.1128/aac.01256.
    PubMed    


  31. YAO S, Wei D, Tang N, Song Y, et al
    Efficient Suppression of Natural Plasmid-Borne Gene Expression in Carbapenem-Resistant Klebsiella pneumoniae Using a Compact CRISPR Interference System.
    Antimicrob Agents Chemother. 2022 Oct 12:e0089022. doi: 10.1128/aac.00890.
    PubMed     Abstract available


  32. PI R, Chen X, Meng J, Liu Q, et al
    Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Oct 3:e0103422. doi: 10.1128/aac.01034.
    PubMed     Abstract available


  33. RAMBACH G, Striednig B, Neurauter M, Hermann M, et al
    Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.
    Antimicrob Agents Chemother. 2022 Oct 3:e0068122. doi: 10.1128/aac.00681.
    PubMed     Abstract available


    September 2022
  34. MENDES RE, Hubler C, Kimbrough JH, Kantro V, et al
    In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020).
    Antimicrob Agents Chemother. 2022 Sep 28:e0121422. doi: 10.1128/aac.01214.
    PubMed     Abstract available


  35. YAMADA W, Kim S, Almoslem M, Kim S, et al
    Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
    Antimicrob Agents Chemother. 2022 Sep 27:e0069522. doi: 10.1128/aac.00695.
    PubMed     Abstract available


  36. COX GW, Avery BP, Parmley EJ, Irwin RJ, et al
    A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017.
    Antimicrob Agents Chemother. 2022 Sep 27:e0067722. doi: 10.1128/aac.00677.
    PubMed     Abstract available


  37. CUSUMANO JA, Daffinee KE, Piehl EC, Garcia-Solache M, et al
    Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.
    Antimicrob Agents Chemother. 2022 Sep 26:e0042622. doi: 10.1128/aac.00426.
    PubMed     Abstract available


  38. RUEGSEGGER L, Xiao J, Naziripour A, Kanumuambidi T, et al
    Multidrug-Resistant Gram-Negative Bacteria in Burn Patients.
    Antimicrob Agents Chemother. 2022;66:e0068822.
    PubMed     Abstract available


  39. LIU F, Gao J, Gao M, Liu Y, et al
    Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Antimicrob Agents Chemother. 2022;66:e0203321.
    PubMed     Abstract available


  40. MADANI A, Negatu DA, El Marrouni A, Miller RR, et al
    Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2022;66:e0066922.
    PubMed     Abstract available


  41. KARLOWSKY JA, Hackel MA, McLeod SM, Miller AA, et al
    In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
    Antimicrob Agents Chemother. 2022;66:e0078122.
    PubMed     Abstract available


  42. HOBSON CA, Pierrat G, Tenaillon O, Bonacorsi S, et al
    Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
    Antimicrob Agents Chemother. 2022;66:e0044722.
    PubMed     Abstract available


  43. JEN FE, Edwards JL, El-Deeb IM, Walker MJ, et al
    Repurposing the Ionophore, PBT2, for Treatment of Multidrug-Resistant Neisseria gonorrhoeae Infections.
    Antimicrob Agents Chemother. 2022;66:e0231821.
    PubMed     Abstract available


  44. PARK S, Russo R, Westfall L, Shrestha R, et al
    A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant Neisseria gonorrhoeae and Other High-Threat Pathogens.
    Antimicrob Agents Chemother. 2022;66:e0041422.
    PubMed     Abstract available


  45. LEWIS JS 2ND, Wiederhold NP, Hakki M, Thompson GR 3rd, et al
    New Perspectives on Antimicrobial Agents: Isavuconazole.
    Antimicrob Agents Chemother. 2022;66:e0017722.
    PubMed     Abstract available


  46. WU W, He S, Li A, Guo Q, et al
    A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo.
    Antimicrob Agents Chemother. 2022;66:e0060122.
    PubMed     Abstract available


  47. CHAE G, Park YE, Chong YP, Lee HJ, et al
    Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
    Antimicrob Agents Chemother. 2022;66:e0226121.
    PubMed     Abstract available


  48. BROWN-ELLIOTT BA, Wallace RJ Jr
    In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.
    Antimicrob Agents Chemother. 2022;66:e0068922.
    PubMed     Abstract available


  49. LUTERBACH CL, Qiu H, Hanafin PO, Sharma R, et al
    A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Antimicrob Agents Chemother. 2022 Sep 20:e0059122. doi: 10.1128/aac.00591.
    PubMed     Abstract available


  50. ZOU J, Chen S, Rao W, Fu L, et al
    Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
    Antimicrob Agents Chemother. 2022 Sep 15:e0081122. doi: 10.1128/aac.00811.
    PubMed     Abstract available


  51. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
    Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
    PubMed     Abstract available


  52. STANTON RA, Campbell D, McAllister GA, Breaker E, et al
    Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected through CDC's Emerging Infections Program, United States, 2016-2018.
    Antimicrob Agents Chemother. 2022 Sep 6:e0049622. doi: 10.1128/aac.00496.
    PubMed     Abstract available


    August 2022
  53. KIM LH, Kang SM, Whang J, Kwon KW, et al
    Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.
    Antimicrob Agents Chemother. 2022 Aug 30:e0076222. doi: 10.1128/aac.00762.
    PubMed     Abstract available


  54. SHEE S, Singh S, Tripathi A, Thakur C, et al
    Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species.
    Antimicrob Agents Chemother. 2022 Aug 17:e0059222. doi: 10.1128/aac.00592.
    PubMed     Abstract available


  55. SARIS A, Qin W, van Linge CCA, Reijnders TDY, et al
    The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2022 Aug 16:e0229821. doi: 10.1128/aac.02298.
    PubMed     Abstract available


  56. POIREL L, Ortiz de la Rosa JM, Sakaoglu Z, Kusaksizoglu A, et al
    NDM-35-Producing ST167 Escherichia coli Highly Resistant to beta-Lactams Including Cefiderocol.
    Antimicrob Agents Chemother. 2022;66:e0031122.
    PubMed     Abstract available


  57. MENON ND, Penziner S, Montano ET, Zurich R, et al
    Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2022;66:e0023922.
    PubMed     Abstract available


  58. MCPHERSON J, Hu C, Begum K, Wang W, et al
    Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.
    Antimicrob Agents Chemother. 2022;66:e0224421.
    PubMed     Abstract available


  59. OSTAPSKA H, Raju D, Corsini R, Lehoux M, et al
    Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases as Antibiofilm Agents in Acute Pulmonary Pseudomonas aeruginosa Infection.
    Antimicrob Agents Chemother. 2022;66:e0005222.
    PubMed     Abstract available


  60. COSTA DVS, Pham NVS, Hays RA, Bolick DT, et al
    Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Antimicrob Agents Chemother. 2022;66:e0048922.
    PubMed     Abstract available


  61. WIEDERHOLD NP, Patterson TF, Rebholz S, Boal CWC, et al
    The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).
    Antimicrob Agents Chemother. 2022;66:e0052122.
    PubMed     Abstract available


  62. CHOCHUA S, Metcalf B, Li Z, Mathis S, et al
    Invasive Group A Streptococcal Penicillin Binding Protein 2x Variants Associated with Reduced Susceptibility to beta-Lactam Antibiotics in the United States, 2015-2021.
    Antimicrob Agents Chemother. 2022 Aug 15:e0080222. doi: 10.1128/aac.00802.
    PubMed     Abstract available


  63. GEBERETSADIK G, Inaizumi A, Nishiyama A, Yamaguchi T, et al
    Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs.
    Antimicrob Agents Chemother. 2022 Aug 15:e0017122. doi: 10.1128/aac.00171.
    PubMed     Abstract available


  64. VALCEK A, Nesporova K, Whiteway C, De Pooter T, et al
    Genomic Analysis of a Strain Collection Containing Multidrug-, Extensively Drug-, Pandrug-, and Carbapenem-Resistant Modern Clinical Isolates of Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2022 Aug 15:e0089222. doi: 10.1128/aac.00892.
    PubMed     Abstract available


  65. BRUNAUGH AD, Walz A, Warnken Z, Pearce C, et al
    Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.
    Antimicrob Agents Chemother. 2022 Aug 9:e0018622. doi: 10.1128/aac.00186.
    PubMed     Abstract available


  66. BARNIER JP, Saidjalolov S, Bouchet F, Mayer L, et al
    Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 9:e0235721. doi: 10.1128/aac.02357.
    PubMed     Abstract available


  67. YUN HY, Chang MJ, Jung H, Chang V, et al
    Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
    Antimicrob Agents Chemother. 2022 Aug 8:e0189321. doi: 10.1128/aac.01893.
    PubMed     Abstract available


  68. DING Y, Zhu H, Fu L, Zhang W, et al
    Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 4:e0065822. doi: 10.1128/aac.00658.
    PubMed     Abstract available


  69. ESCRIBANO P, Gomez A, Reigadas E, Munoz P, et al
    EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.
    Antimicrob Agents Chemother. 2022 Aug 4:e0084922. doi: 10.1128/aac.00849.
    PubMed     Abstract available


  70. POULTON NC, Azadian ZA, DeJesus MA, Rock JM, et al
    Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 3:e0090422. doi: 10.1128/aac.00904.
    PubMed     Abstract available


  71. COLABARDINI AC, Van Rhijn N, LaBella AL, Valero C, et al
    Aspergillus fumigatus FhdA Transcription Factor Is Important for Mitochondrial Activity and Codon Usage Regulation during the Caspofungin Paradoxical Effect.
    Antimicrob Agents Chemother. 2022 Aug 2:e0070122. doi: 10.1128/aac.00701.
    PubMed     Abstract available


  72. EDLIND T, Katiyar S
    Intrinsically High Resistance of Candida glabrata to Hydrogen Peroxide and Its Reversal in a Fluconazole-Resistant Mutant.
    Antimicrob Agents Chemother. 2022 Aug 2:e0072122. doi: 10.1128/aac.00721.
    PubMed    


  73. GRACIAA DS, Kipiani M, Magee MJ, Mikiashvili L, et al
    Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 2:e0040822. doi: 10.1128/aac.00408.
    PubMed     Abstract available


    July 2022
  74. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
    Correction for Shelton et al., "Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2022 Jul 25:e0096222. doi: 10.1128/aac.00962.
    PubMed    


  75. CHANG SC, Lin LC, Lu JJ
    An lnu(A)-Carrying Multi-Resistance Plasmid Derived from Sequence Type 3 Methicillin-Resistant Staphylococcus lugdunensis May Contribute to Antimicrobial Resistance in Staphylococci.
    Antimicrob Agents Chemother. 2022 Jul 25:e0019722. doi: 10.1128/aac.00197.
    PubMed     Abstract available


  76. HARISH E, Sarkar A, Handelman M, Abo Kandil A, et al
    Triazole Priming as an Adaptive Response and Gateway to Resistance in Aspergillus fumigatus.
    Antimicrob Agents Chemother. 2022 Jul 20:e0045822. doi: 10.1128/aac.00458.
    PubMed     Abstract available


  77. LOPEZ-CERERO L, Stolz E, Pulido MR, Pascual A, et al
    Characterization of Extended-Spectrum beta-Lactamase-Producing Shigella sonnei in Spain: Expanding the Geographic Distribution of Sequence Type 152/CTX-M-27 Clone.
    Antimicrob Agents Chemother. 2022;66:e0033422.
    PubMed     Abstract available


  78. DAI YY, Qin C, Huang GR, Qin YC, et al
    Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori.
    Antimicrob Agents Chemother. 2022;66:e0007322.
    PubMed     Abstract available


  79. MADDEN GR, Petri WA Jr, Costa DVS, Warren CA, et al
    Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.
    Antimicrob Agents Chemother. 2022;66:e0067622.
    PubMed     Abstract available


  80. O'DONNELL JN, Lodise TP
    New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
    Antimicrob Agents Chemother. 2022;66:e0025622.
    PubMed     Abstract available


  81. SEN T, Verma NK
    Functional Role of YnfA, an Efflux Transporter in Resistance to Antimicrobial Agents in Shigella flexneri.
    Antimicrob Agents Chemother. 2022;66:e0029322.
    PubMed     Abstract available


  82. PARK JJ, Jung EJ, Kim JY, Seo YB, et al
    Thirty-Day Mortality Rates in Patients with Extended-Spectrum beta-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems.
    Antimicrob Agents Chemother. 2022;66:e0028722.
    PubMed     Abstract available


  83. DESAI JV, Urban A, Swaim DZ, Colton B, et al
    Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis.
    Antimicrob Agents Chemother. 2022;66:e0030822.
    PubMed     Abstract available


  84. GEBREMARIAM T, Gu Y, Alkhazraji S, Youssef E, et al
    The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections.
    Antimicrob Agents Chemother. 2022;66:e0038022.
    PubMed     Abstract available


  85. PITOUT JDD, Peirano G, Chen L, DeVinney R, et al
    Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.
    Antimicrob Agents Chemother. 2022;66:e0051122.
    PubMed     Abstract available


  86. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    PubMed     Abstract available


  87. DIAZ-GARCIA J, Gomez A, Alcala L, Reigadas E, et al
    Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.
    Antimicrob Agents Chemother. 2022 Jul 19:e0071022. doi: 10.1128/aac.00710.
    PubMed     Abstract available


  88. MEHTA K, Guo T, Wallis RS, van der Graaf PH, et al
    Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
    Antimicrob Agents Chemother. 2022 Jul 14:e0036622. doi: 10.1128/aac.00366.
    PubMed     Abstract available


  89. KONG X, Wang B, Chen X, Wang L, et al
    Hinokiflavone Attenuates the Virulence of Methicillin-Resistant Staphylococcus aureus by Targeting Caseinolytic Protease P.
    Antimicrob Agents Chemother. 2022 Jul 11:e0024022. doi: 10.1128/aac.00240.
    PubMed     Abstract available


  90. KNOLL MA, Samardzic E, Posch W, Lass-Florl C, et al
    Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata.
    Antimicrob Agents Chemother. 2022 Jul 11:e0016822. doi: 10.1128/aac.00168.
    PubMed     Abstract available


  91. SOUCHE A, Kolenda C, Teoli J, Schuch R, et al
    Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.
    Antimicrob Agents Chemother. 2022 Jul 11:e0058822. doi: 10.1128/aac.00588.
    PubMed     Abstract available


  92. WATANABE F, Furuuchi K, Hanada K, Fujiwara K, et al
    Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
    Antimicrob Agents Chemother. 2022 Jul 7:e0044122. doi: 10.1128/aac.00441.
    PubMed     Abstract available


    June 2022
  93. JACOBS SE, Jacobs JL, Dennis EK, Taimur S, et al
    Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.
    Antimicrob Agents Chemother. 2022 Jun 30:e0005322. doi: 10.1128/aac.00053.
    PubMed     Abstract available


  94. HSU AJ, Tamma PD, Fisher BT
    Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
    Antimicrob Agents Chemother. 2022 Jun 29:e0215621. doi: 10.1128/aac.02156.
    PubMed     Abstract available


  95. BAE S, Kim ES, Kim HS, Yang E, et al
    Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.
    Antimicrob Agents Chemother. 2022 Jun 28:e0012622. doi: 10.1128/aac.00126.
    PubMed     Abstract available


  96. RIVIERE E, Verboven L, Dippenaar A, Goossens S, et al
    Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
    Antimicrob Agents Chemother. 2022 Jun 27:e0032222. doi: 10.1128/aac.00322.
    PubMed     Abstract available


  97. KWIECINSKI JM, Jelani DA, Fuentes EJ, Horswill AR, et al
    Therapeutic Inhibition of Staphylococcus aureus ArlRS Two-Component Regulatory System Blocks Virulence.
    Antimicrob Agents Chemother. 2022 Jun 23:e0018722. doi: 10.1128/aac.00187.
    PubMed     Abstract available


  98. ABOLHASSANI-CHIMEH R, Akkerman OW, Saktiawati AMI, Punt NC, et al
    Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2022 Jun 21:e0000322. doi: 10.1128/aac.00003.
    PubMed     Abstract available


  99. PHILLIPS EC, Warren CA, Ma JZ, Madden GR, et al
    Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.
    Antimicrob Agents Chemother. 2022;66:e0000122.
    PubMed     Abstract available


  100. RIMAL B, Batchelder HR, Story-Roller E, Panthi CM, et al
    T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with beta-Lactams Imipenem and Cefditoren.
    Antimicrob Agents Chemother. 2022;66:e0053622.
    PubMed     Abstract available


  101. XIE J, Yang Q, Han X, Dong Y, et al
    Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
    Antimicrob Agents Chemother. 2022;66:e0009922.
    PubMed     Abstract available


  102. WILLIAMS E, Zhang B, Chow EPF, Chea S, et al
    Inhibitory Activity of Antibacterial Mouthwashes and Antiseptic Substances against Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 2022;66:e0004222.
    PubMed     Abstract available


  103. HUGGINS JP, Pease R, Stanly K, Workman A, et al
    Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
    Antimicrob Agents Chemother. 2022;66:e0028322.
    PubMed     Abstract available


  104. TRAN TT, Gomez Villegas S, Aitken SL, Butler-Wu SM, et al
    New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
    Antimicrob Agents Chemother. 2022;66:e0261420.
    PubMed     Abstract available


  105. WALTER K, Kokesch-Himmelreich J, Treu A, Waldow F, et al
    Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
    Antimicrob Agents Chemother. 2022;66:e0158821.
    PubMed     Abstract available


  106. TONG K, Wei J, Gu H, Hu Q, et al
    Evaluation of Experimental and Clinical Efficacy on Surgical Debridement and Systemic Antibiotics Treatment for Early Knee Infection after Anterior Cruciate Ligament Reconstruction.
    Antimicrob Agents Chemother. 2022;66:e0011222.
    PubMed     Abstract available


  107. MCCALLIN S, Menzi C, Lassen S, Daraspe J, et al
    Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA).
    Antimicrob Agents Chemother. 2022 Jun 16:e0224721. doi: 10.1128/aac.02247.
    PubMed     Abstract available


  108. DOORLEY LA, Rybak JM, Berkow EL, Zhang Q, et al
    Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.
    Antimicrob Agents Chemother. 2022 Jun 14:e0028922. doi: 10.1128/aac.00289.
    PubMed     Abstract available


  109. SONG W, Wang L, Jin M, Guo X, et al
    Punicalagin, an Inhibitor of Sortase A, Is a Promising Therapeutic Drug to Combat Methicillin-Resistant Staphylococcus aureus Infections.
    Antimicrob Agents Chemother. 2022 Jun 2:e0022422. doi: 10.1128/aac.00224.
    PubMed     Abstract available


  110. SHIVARATHRI R, Jenull S, Chauhan M, Singh A, et al
    Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.
    Antimicrob Agents Chemother. 2022 Jun 2:e0227621. doi: 10.1128/aac.02276.
    PubMed     Abstract available


  111. SHAO Y, Chen M, Luo J, Li D, et al
    Serogroup Y Clonal Complex 23 Meningococcus in China Acquiring Penicillin Resistance from Commensal Neisseria lactamica Species.
    Antimicrob Agents Chemother. 2022 Jun 2:e0238321. doi: 10.1128/aac.02383.
    PubMed     Abstract available


  112. ZHOU Y, Zhong Z, Hu S, Wang J, et al
    A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.
    Antimicrob Agents Chemother. 2022 Jun 2:e0218821. doi: 10.1128/aac.02188.
    PubMed     Abstract available


  113. CHEN M, Zhong G, Wang S, Chen P, et al
    Deletion of cox7c Results in Pan-Azole Resistance in Aspergillus fumigatus.
    Antimicrob Agents Chemother. 2022 Jun 1:e0015122. doi: 10.1128/aac.00151.
    PubMed     Abstract available


  114. ISHIKAWA K, Uehara Y, Mori N, Mikami Y, et al
    In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2022 Jun 1:e0012522. doi: 10.1128/aac.00125.
    PubMed     Abstract available


    May 2022
  115. NUERMBERGER EL, Martinez-Martinez MS, Sanz O, Urones B, et al
    GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2022 May 24:e0013222. doi: 10.1128/aac.00132.
    PubMed     Abstract available


  116. SOBEL JD, Akins R
    Determining Susceptibility in Candida Vaginal Isolates.
    Antimicrob Agents Chemother. 2022 May 23:e0236621. doi: 10.1128/aac.02366.
    PubMed     Abstract available


  117. KARLOWSKY JA, Lob SH, DeRyke CA, Hilbert DW, et al
    In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 202
    Antimicrob Agents Chemother. 2022;66:e0018922.
    PubMed     Abstract available


  118. LI X, Le W, Lou X, Genco CA, et al
    In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019).
    Antimicrob Agents Chemother. 2022;66:e0010922.
    PubMed     Abstract available


  119. MURRAY GL, Bodiyabadu K, Vodstrcil LA, Machalek DA, et al
    parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure.
    Antimicrob Agents Chemother. 2022;66:e0027822.
    PubMed     Abstract available


  120. PRASAD NK, Seiple IB, Cirz RT, Rosenberg OS, et al
    Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.
    Antimicrob Agents Chemother. 2022;66:e0005422.
    PubMed     Abstract available


  121. GAO W, Passarell J, Patel YT, Zhang Z, et al
    Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
    Antimicrob Agents Chemother. 2022;66:e0139921.
    PubMed     Abstract available


  122. PAUL A, Nair RR, Jakkala K, Pradhan A, et al
    Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate De Novo Emergence of Genetic Resisters to Antibiotics.
    Antimicrob Agents Chemother. 2022;66:e0228521.
    PubMed     Abstract available


  123. HUJER AM, Bethel CR, Taracila MA, Marshall SH, et al
    Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant beta-Lactamases and Their Increasing Importance.
    Antimicrob Agents Chemother. 2022;66:e0179021.
    PubMed     Abstract available


  124. SCHULTHESS B, Akdogan Kittana FN, Homke R, Sander P, et al
    In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2022;66:e0234621.
    PubMed     Abstract available


  125. CHUA TP, Danielewski J, Bodiyabadu K, Bradshaw CS, et al
    Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment.
    Antimicrob Agents Chemother. 2022;66:e0024322.
    PubMed     Abstract available


  126. LANDLINGER C, Oberbauer V, Podpera Tisakova L, Schwebs T, et al
    Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance.
    Antimicrob Agents Chemother. 2022;66:e0231921.
    PubMed     Abstract available


  127. DESNOS-OLLIVIER M, Bretagne S, Lortholary O, Dromer F, et al
    Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.
    Antimicrob Agents Chemother. 2022;66:e0172521.
    PubMed     Abstract available


  128. KARABA SM, Hirsch EB, Heil EL
    In a Pinch: Cefiderocol for CRAB Infections.
    Antimicrob Agents Chemother. 2022;66:e0006522.
    PubMed     Abstract available


  129. KARABASEVIC N, Roberts JA, Stronach L, Naicker S, et al
    Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.
    Antimicrob Agents Chemother. 2022;66:e0214021.
    PubMed     Abstract available


  130. ERSOY SC, Manna AC, Proctor RA, Chambers HF, et al
    The NaHCO3-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype.
    Antimicrob Agents Chemother. 2022 May 16:e0025222. doi: 10.1128/aac.00252.
    PubMed     Abstract available


  131. SUPANDY A, Mehta HH, Tran TT, Miller WR, et al
    Evolution of Enterococcus faecium in Response to a Combination of Daptomycin and Fosfomycin Reveals Distinct and Diverse Adaptive Strategies.
    Antimicrob Agents Chemother. 2022 May 11:e0233321. doi: 10.1128/aac.02333.
    PubMed     Abstract available


  132. FUCHS F, Aldejohann AM, Hoffmann AM, Walther G, et al
    In Vitro Activity of Nitroxoline in Antifungal-Resistant Candida Species Isolated from the Urinary Tract.
    Antimicrob Agents Chemother. 2022 May 11:e0226521. doi: 10.1128/aac.02265.
    PubMed     Abstract available


  133. MOURAD A, Holland TL, Turner NA
    Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?
    Antimicrob Agents Chemother. 2022 May 10:e0036522. doi: 10.1128/aac.00365.
    PubMed     Abstract available


  134. CONKLE-GUTIERREZ D, Kim C, Ramirez-Busby SM, Modlin SJ, et al
    Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
    Antimicrob Agents Chemother. 2022 May 9:e0207521. doi: 10.1128/aac.02075.
    PubMed     Abstract available


  135. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    PubMed     Abstract available


    April 2022
  136. RAGUNATHAN P, Dick T, Gruber G
    Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.
    Antimicrob Agents Chemother. 2022 Apr 28:e0001822. doi: 10.1128/aac.00018.
    PubMed     Abstract available


  137. MADDEN DE, Olagoke O, Baird T, Neill J, et al
    Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2022 Apr 25:e0020422. doi: 10.1128/aac.00204.
    PubMed     Abstract available


  138. HOLLEY CL, Dhulipala V, Balthazar JT, Le Van A, et al
    A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 2022 Apr 25:e0025122. doi: 10.1128/aac.00251.
    PubMed     Abstract available


  139. SALAMA OE, Gerstein AC
    Differential Response of Candida Species Morphologies and Isolates to Fluconazole and Boric Acid.
    Antimicrob Agents Chemother. 2022 Apr 21:e0240621. doi: 10.1128/aac.02406.
    PubMed     Abstract available


  140. ROUCHON CN, Harris J, Zubair-Nizami Z, Weinstein AJ, et al
    The Cationic Antimicrobial Peptide Activity of Lysozyme Reduces Viable Enterococcus faecalis Cells in Biofilms.
    Antimicrob Agents Chemother. 2022 Apr 21:e0233921. doi: 10.1128/aac.02339.
    PubMed     Abstract available


  141. SRIVASTAVA S, Boorgula GD, Wang JY, Huang HL, et al
    Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
    Antimicrob Agents Chemother. 2022;66:e0232021.
    PubMed     Abstract available


  142. POIREL L, Ortiz de la Rosa JM, Sadek M, Nordmann P, et al
    Impact of Acquired Broad-Spectrum beta-Lactamases on Susceptibility to Cefiderocol and Newly Developed beta-Lactam/beta-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2022;66:e0003922.
    PubMed     Abstract available


  143. RAJA SM, Guptill JT, Juel VC, Walter EB, et al
    First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.
    Antimicrob Agents Chemother. 2022;66:e0173221.
    PubMed     Abstract available


  144. TARACILA MA, Bethel CR, Hujer AM, Papp-Wallace KM, et al
    Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC beta-Lactamase.
    Antimicrob Agents Chemother. 2022;66:e0212421.
    PubMed     Abstract available


  145. KUREPINA N, Chen L, Composto K, Rifat D, et al
    CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on beta-Lactam Susceptibility.
    Antimicrob Agents Chemother. 2022;66:e0009322.
    PubMed     Abstract available


  146. LIPORAGI LOPES LC, Korangath P, Dos Santos SR Jr, Gabrielson KL, et al
    Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus neoformans Pneumonia.
    Antimicrob Agents Chemother. 2022;66:e0239921.
    PubMed     Abstract available


  147. MOON SM, Kim SY, Kim DH, Huh HJ, et al
    Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.
    Antimicrob Agents Chemother. 2022;66:e0202721.
    PubMed     Abstract available


  148. ANDRADE ESN, Brandao JG, Silva JSD, Coriolano CRF, et al
    Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan.
    Antimicrob Agents Chemother. 2022 Apr 18:e0217021. doi: 10.1128/aac.02170.
    PubMed     Abstract available


  149. EICHENSEHER F, Herpers BL, Badoux P, Leyva-Castillo JM, et al
    Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus In Vitro, on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection.
    Antimicrob Agents Chemother. 2022 Apr 13:e0227321. doi: 10.1128/aac.02273.
    PubMed     Abstract available


  150. CAFFREY AR, Appaneal HJ, LaPlante KL, Lopes VV, et al
    Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study.
    Antimicrob Agents Chemother. 2022 Apr 13:e0211721. doi: 10.1128/aac.02117.
    PubMed     Abstract available


  151. GARCIA-PRATS AJ, Frias M, van der Laan L, De Leon A, et al
    Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
    Antimicrob Agents Chemother. 2022 Apr 11:e0214421. doi: 10.1128/aac.02144.
    PubMed     Abstract available


  152. CHAUHAN U, Barth VC, Woychik NA
    tRNA(fMet) Inactivating Mycobacterium tuberculosis VapBC Toxin-Antitoxin Systems as Therapeutic Targets.
    Antimicrob Agents Chemother. 2022 Apr 11:e0189621. doi: 10.1128/aac.01896.
    PubMed     Abstract available


  153. ZHANG T, Yu X, Wen S, Xue Y, et al
    Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.
    Antimicrob Agents Chemother. 2022 Apr 11:e0222421. doi: 10.1128/aac.02224.
    PubMed     Abstract available


  154. VAN VLIET AHM, Thakur S, Prada JM, Mehat JW, et al
    Genomic Screening of Antimicrobial Resistance Markers in UK and US Campylobacter Isolates Highlights Stability of Resistance over an 18-Year Period.
    Antimicrob Agents Chemother. 2022 Apr 11:e0168721. doi: 10.1128/aac.01687.
    PubMed     Abstract available


    March 2022
  155. LIN X, Qin X, Wu X, Liao Y, et al
    Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.
    Antimicrob Agents Chemother. 2022 Mar 29:e0229421. doi: 10.1128/aac.02294.
    PubMed     Abstract available


  156. SONG N, Zhou X, Li D, Li X, et al
    A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.
    Antimicrob Agents Chemother. 2022 Mar 28:e0210521. doi: 10.1128/aac.02105.
    PubMed     Abstract available


  157. LI J, Coste AT, Bachmann D, Sanglard D, et al
    Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris.
    Antimicrob Agents Chemother. 2022 Mar 28:e0006722. doi: 10.1128/aac.00067.
    PubMed     Abstract available


  158. TASNEEN R, Garcia A, Converse PJ, Zimmerman MD, et al
    Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Antimicrob Agents Chemother. 2022 Mar 22:e0239821. doi: 10.1128/aac.02398.
    PubMed     Abstract available


  159. JI X, Kruger H, Wang Y, Fessler AT, et al
    Tn560, a Novel Tn554 Family Transposon from Porcine Methicillin-Resistant Staphylococcus aureus ST398, Carries a Multiresistance Gene Cluster Comprising a Novel spc Gene Variant and the Genes lsa(E) and lnu(B).
    Antimicrob Agents Chemother. 2022 Mar 22:e0194721. doi: 10.1128/aac.01947.
    PubMed    


  160. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    PubMed     Abstract available


  161. ROTHSTEIN TE, Cunningham SA, Rieke RA, Mainella JM, et al
    Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.
    Antimicrob Agents Chemother. 2022 Mar 21:e0243221. doi: 10.1128/aac.02432.
    PubMed     Abstract available


  162. BILAL H, Tait JR, Lang Y, Zhou J, et al
    Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Antimicrob Agents Chemother. 2022;66:e0220321.
    PubMed     Abstract available


  163. BLASCO L, Bleriot I, Gonzalez de Aledo M, Fernandez-Garcia L, et al
    Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host.
    Antimicrob Agents Chemother. 2022;66:e0192321.
    PubMed     Abstract available


  164. BUTLER MS, Gigante V, Sati H, Paulin S, et al
    Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
    Antimicrob Agents Chemother. 2022;66:e0199121.
    PubMed     Abstract available


  165. KURBATFINSKI N, Goodman SD, Bakaletz LO
    A Humanized Monoclonal Antibody Potentiates Killing of Diverse Biofilm-Forming Respiratory Tract Pathogens by Antibiotics.
    Antimicrob Agents Chemother. 2022;66:e0187721.
    PubMed     Abstract available


  166. APPANEAL HJ, Lopes VV, LaPlante KL, Caffrey AR, et al
    Treatment, Clinical Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients with Acinetobacter baumannii Infection.
    Antimicrob Agents Chemother. 2022;66:e0197521.
    PubMed     Abstract available


  167. LI Y, Zhang L, Xiu L, Wang D, et al
    A Multiplex Molecular Assay for Detection of Six penA Codons To Predict Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 2022;66:e0170921.
    PubMed     Abstract available


  168. SAWATZKY P, Demczuk W, Lefebvre B, Allen V, et al
    Increasing Azithromycin Resistance in Neisseria gonorrhoeae Due to NG-MAST 12302 Clonal Spread in Canada, 2015 to 2018.
    Antimicrob Agents Chemother. 2022;66:e0168821.
    PubMed     Abstract available


  169. PALLIYIL S, Mawer M, Alawfi SA, Fogg L, et al
    Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model.
    Antimicrob Agents Chemother. 2022 Mar 14:e0195721. doi: 10.1128/aac.01957.
    PubMed     Abstract available


  170. LI LH, Lu HF, Liu YF, Lin YT, et al
    FadACB and smeU1VWU2X Contribute to Oxidative Stress-Mediated Fluoroquinolone Resistance in Stenotrophomonas maltophilia.
    Antimicrob Agents Chemother. 2022 Mar 14:e0204321. doi: 10.1128/aac.02043.
    PubMed     Abstract available


  171. BASARAB GS, Ghorpade S, Gibhard L, Mueller R, et al
    Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
    Antimicrob Agents Chemother. 2022 Mar 10:e0219221. doi: 10.1128/aac.02192.
    PubMed     Abstract available


  172. KLEINHENZ M, Beesetty P, Yang C, Li Z, et al
    Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.
    Antimicrob Agents Chemother. 2022 Mar 10:e0227021. doi: 10.1128/aac.02270.
    PubMed     Abstract available


  173. SHELTON C, McNeil M, Allen R, Flint L, et al
    Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Mar 9:e0204121. doi: 10.1128/aac.02041.
    PubMed     Abstract available


  174. VAHEDI-SHAHANDASHTI R, Dietl AM, Binder U, Nagl M, et al
    Aspergillus terreus and the Interplay with Amphotericin B: from Resistance to Tolerance?
    Antimicrob Agents Chemother. 2022 Mar 7:e0227421. doi: 10.1128/aac.02274.
    PubMed     Abstract available


  175. SCHARN CR, Tickler IA, Tenover FC, Goering RV, et al
    Characterization of SCCmec Instability in Methicillin-Resistant Staphylococcus aureus Affecting Adjacent Chromosomal Regions, Including the Gene for Staphylococcal Protein A (spa).
    Antimicrob Agents Chemother. 2022 Mar 7:e0237421. doi: 10.1128/aac.02374.
    PubMed     Abstract available


    February 2022
  176. LEE JH, Park YE, Chong YP, Shim TS, et al
    Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
    Antimicrob Agents Chemother. 2022;66:e0152221.
    PubMed     Abstract available


  177. RUEDAS-LOPEZ A, Alonso-Garcia I, Lasarte-Monterrubio C, Guijarro-Sanchez P, et al
    Selection of AmpC beta-Lactamase Variants and Metallo-beta-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Antimicrob Agents Chemother. 2022;66:e0206721.
    PubMed     Abstract available


  178. SELCHOW P, Ordway DJ, Verma D, Whittel N, et al
    Apramycin Overcomes the Inherent Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2022;66:e0151021.
    PubMed     Abstract available


  179. DAS S, Bush K
    Success and Challenges Associated with Large-Scale Collaborative Surveillance for Carbapenemase Genes in Gram-Negative Bacteria.
    Antimicrob Agents Chemother. 2022;66:e0229921.
    PubMed     Abstract available


  180. TAKAMATSU A, Yaguchi T, Tagashira Y, Watanabe A, et al
    Nocardiosis in Japan: a Multicentric Retrospective Cohort Study.
    Antimicrob Agents Chemother. 2022;66:e0189021.
    PubMed     Abstract available


  181. BIZOT E, Cointe A, Bidet P, Mariani-Kurkdjian P, et al
    Azithromycin Resistance in Shiga Toxin-Producing Escherichia coli in France between 2004 and 2020 and Detection of mef(C)-mph(G) Genes.
    Antimicrob Agents Chemother. 2022;66:e0194921.
    PubMed     Abstract available


  182. CHUMBITA M, Puerta-Alcalde P, Gudiol C, Garcia-Pouton N, et al
    Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.
    Antimicrob Agents Chemother. 2022;66:e0174421.
    PubMed     Abstract available


    January 2022
  183. BERG A, Clary J, Hanna D, Nuermberger E, et al
    Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database.
    Antimicrob Agents Chemother. 2022 Jan 31:AAC0179321. doi: 10.1128/AAC.01793.
    PubMed     Abstract available


  184. KAYA F, Ernest JP, LoMauro K, Gengenbacher M, et al
    A rabbit model to study antibiotic penetration at the site of infection for non-tuberculous mycobacterial lung disease: macrolide case study.
    Antimicrob Agents Chemother. 2022 Jan 31:aac0221221. doi: 10.1128/aac.02212.
    PubMed     Abstract available


  185. KLINE A, Lionakis MS
    Case Commentary: Long-term fosmanogepix use in a transplant recipient with disseminated aspergillosis caused by azole-resistant Aspergillus calidoustus.
    Antimicrob Agents Chemother. 2022 Jan 24:aac0236821. doi: 10.1128/aac.02368.
    PubMed     Abstract available


  186. DOMENECH P, Mouhoub E, Reed MB
    Experimental confirmation that an uncommon rrs gene mutation (g878a) of Mycobacterium tuberculosis confers resistance to streptomycin.
    Antimicrob Agents Chemother. 2022 Jan 24:AAC0191521. doi: 10.1128/AAC.01915.
    PubMed     Abstract available


  187. KIMURA M, Asano-Mori Y, Sakoh T, Abe M, et al
    Factors associated with breakthrough fungemia caused by Candida, Trichosporon, or Fusarium species when the breakthrough fungemia developed in patients with hematological disorders.
    Antimicrob Agents Chemother. 2022 Jan 18:AAC0208121. doi: 10.1128/AAC.02081.
    PubMed     Abstract available


  188. LEW C, Pellitteri Hahn M, Scarlett C, Rottier A, et al
    Proteomic Correlates of Enhanced Daptomycin Activity Following beta-Lactam Pre-Conditioning in Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2022 Jan 18:AAC0201721. doi: 10.1128/AAC.02017.
    PubMed     Abstract available


  189. BAO X, Bove M, Coenye T
    Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
    Antimicrob Agents Chemother. 2022;66:e0187521.
    PubMed     Abstract available


  190. CRANE SD, Banerjee SK, Pechous RD
    Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.
    Antimicrob Agents Chemother. 2022;66:e0127521.
    PubMed     Abstract available


  191. PHAN JR, Do DM, Truong MC, Ngo C, et al
    An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.
    Antimicrob Agents Chemother. 2022;66:e0143521.
    PubMed     Abstract available


  192. WULLNER D, Gesper M, Haupt A, Liang X, et al
    Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics.
    Antimicrob Agents Chemother. 2022;66:e0087821.
    PubMed     Abstract available


  193. MCCONVILLE TH, Austin ED, Geng W, Shi Q, et al
    In Vitro Cytotoxicity and Clinical Correlates of MRSA Bacteremia.
    Antimicrob Agents Chemother. 2022;66:e0155921.
    PubMed     Abstract available


  194. ARAGAW WW, Roubert C, Fontaine E, Lagrange S, et al
    Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.
    Antimicrob Agents Chemother. 2022;66:e0140021.
    PubMed     Abstract available


  195. BONNET PL, Le Gal S, Hoffmann CV, Morio F, et al
    Highly Conserved gsc1 Gene of Pneumocystis jirovecii in Patients with or without Prior Exposure to Echinocandins.
    Antimicrob Agents Chemother. 2022;66:e0156321.
    PubMed     Abstract available


  196. ZHENG H, Wang Y, He W, Li F, et al
    In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria.
    Antimicrob Agents Chemother. 2022;66:e0181021.
    PubMed    


  197. YU R, Chen Z, Schwarz S, Yao H, et al
    Mobilization of tet(X4) by IS1 Family Elements in Porcine Escherichia coli Isolates.
    Antimicrob Agents Chemother. 2022;66:e0159721.
    PubMed     Abstract available


  198. SINDELDECKER D, Prakash S, Stoodley P
    Exploration of the Pharmacodynamics for Pseudomonas aeruginosa Biofilm Eradication by Tobramycin.
    Antimicrob Agents Chemother. 2022;66:e0137121.
    PubMed     Abstract available


  199. EALES BM, Tam VH
    Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection.
    Antimicrob Agents Chemother. 2022;66:e0199621.
    PubMed     Abstract available


  200. ONG V, Wills S, Watson D, Sandison T, et al
    Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans.
    Antimicrob Agents Chemother. 2022;66:e0139021.
    PubMed     Abstract available


  201. RAO S, Betancourt-Garcia M, Kare-Opaneye YO, Swierczewski BE, et al
    Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy.
    Antimicrob Agents Chemother. 2022;66:e0082421.
    PubMed     Abstract available


  202. NICKLAS DA, Maggioncalda EC, Story-Roller E, Eichelman B, et al
    Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection.
    Antimicrob Agents Chemother. 2022;66:e0170421.
    PubMed     Abstract available


  203. WARRYN L, Pluschke G
    Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.
    Antimicrob Agents Chemother. 2022;66:e0087021.
    PubMed     Abstract available


  204. SCHILDKRAUT JA, Coolen JPM, Burbaud S, Sangen JJN, et al
    RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2022;66:e0150921.
    PubMed     Abstract available


  205. AMBATI S, Pham T, Lewis ZA, Lin X, et al
    DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.
    Antimicrob Agents Chemother. 2022;66:e0146721.
    PubMed     Abstract available


  206. D'AMICO H, Wallace KL, Burgess D, Burgess DS, et al
    Acute Kidney Injury Associated with Area under the Curve versus Trough Monitoring of Vancomycin in Obese Patients.
    Antimicrob Agents Chemother. 2022;66:e0088621.
    PubMed     Abstract available


  207. KOELE SE, van Beek SW, Maartens G, Brust JCM, et al
    Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment.
    Antimicrob Agents Chemother. 2022 Jan 10:AAC0174921. doi: 10.1128/AAC.01749.
    PubMed     Abstract available


  208. KILBURN S, Innes G, Quinn M, Southwick K, et al
    Antifungal Resistance Trends of Candida auris Clinical Isolates, New York-New Jersey, 2016-2020.
    Antimicrob Agents Chemother. 2022 Jan 10:aac0224221. doi: 10.1128/aac.02242.
    PubMed     Abstract available


  209. VU BG, Moye-Rowley WS
    Azole-resistant alleles of ERG11 in Candida glabrata trigger activation of the Pdr1 and Upc2A transcription factors.
    Antimicrob Agents Chemother. 2022 Jan 10:AAC0209821. doi: 10.1128/AAC.02098.
    PubMed     Abstract available


  210. WIRE MB, Jun SY, Jang IJ, Lee SH, et al
    A Phase 1 Study to Evaluate the Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects.
    Antimicrob Agents Chemother. 2022 Jan 10:AAC0184221. doi: 10.1128/AAC.01842.
    PubMed     Abstract available


  211. LONG H, Hu Y, Feng Y, Zong Z, et al
    Genome analysis of Klebsiella oxytoca complex for antimicrobial resistance and virulence genes.
    Antimicrob Agents Chemother. 2022 Jan 10:aac0218321. doi: 10.1128/aac.02183.
    PubMed     Abstract available


  212. SMELTER D, Hayney M, Sakoulas G, Rose W, et al
    Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin 1-beta?
    Antimicrob Agents Chemother. 2022 Jan 3:aac0216621. doi: 10.1128/aac.02166.
    PubMed     Abstract available


    December 2021
  213. NAKANO S, Fujisawa T, Chang B, Ito Y, et al
    Whole-genome analysis-based phylogeographic investigation of Streptococcus pneumoniae serotype 19A sequence type 320 isolates in Japan.
    Antimicrob Agents Chemother. 2021 Dec 20:AAC0139521. doi: 10.1128/AAC.01395.
    PubMed     Abstract available


  214. CAMARGO JF, Jabr R, Anderson AD, Lekakis L, et al
    Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy.
    Antimicrob Agents Chemother. 2021 Dec 20:aac0220621. doi: 10.1128/aac.02206.
    PubMed     Abstract available


  215. TRUONG-BOLDUC QC, Wang Y, Reedy JL, Vyas JM, et al
    Staphylococcus aureus Efflux Pumps and Tolerance to Ciprofloxacin and Chlorhexidine following Induction by Mupirocin.
    Antimicrob Agents Chemother. 2021 Dec 20:AAC0184521. doi: 10.1128/AAC.01845.
    PubMed     Abstract available


  216. CHEN Y, Moran JC, Campbell-Lee S, Horsburgh MJ, et al
    Transcriptomic responses and survival mechanisms of staphylococci to the antimicrobial skin lipid sphingosine.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0056921. doi: 10.1128/AAC.00569.
    PubMed     Abstract available


  217. LACKNER N, Vahedi-Shahandashti R, Jahnig S, Schonherr L, et al
    Echinocandins and their Activity against Aspergillus terreus Species Complex: A Novel Agar Screening Method.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0190921. doi: 10.1128/AAC.01909.
    PubMed     Abstract available


  218. HUANG J, Guo S, Li X, Yuan F, et al
    Nemonoxacin enhances antibacterial activity and anti-resistant mutation ability of vancomycin against methicillin-resistant Staphylococcus aureus in an in vitro dynamic pharmacokinetic/pharmacodynamic model.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0180021. doi: 10.1128/AAC.01800.
    PubMed     Abstract available


  219. AGUIAR-ALVES F, Le HN, Tran VG, Gras E, et al
    Anti-virulence Bispecific Monoclonal Antibody Mediated Protection Against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0202221. doi: 10.1128/AAC.02022.
    PubMed     Abstract available


  220. LYONS MA
    Pharmacodynamics and the Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0163621. doi: 10.1128/AAC.01636.
    PubMed     Abstract available


  221. KIM JS, Kim YH, Lee SH, Kim YH, et al
    Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0168421. doi: 10.1128/AAC.01684.
    PubMed     Abstract available


  222. KHALIFA HO, Hubka V, Watanabe A, Nagi M, et al
    Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei recovered from an International Collection.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0185621. doi: 10.1128/AAC.01856.
    PubMed     Abstract available


  223. VERMA R, Gurumurthy M, Yeo BCM, Lu Q, et al
    Effects of increasing concentrations of rifampicin on different Mycobacterium tuberculosis lineages in a Whole blood Bactericidal Activity Assay.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0169921. doi: 10.1128/AAC.01699.
    PubMed     Abstract available


    November 2021
  224. POON R, Basuino L, Satishkumar N, Chatterjee A, et al
    Loss of GdpP function in Staphylococcus aureus leads to beta-lactam tolerance and enhanced evolution of beta-lactam resistance.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0143121. doi: 10.1128/AAC.01431.
    PubMed     Abstract available


  225. SASAKI T, Svensson EM, Wang X, Wang Y, et al
    Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0160821. doi: 10.1128/AAC.01608.
    PubMed     Abstract available


  226. CARVALHAES CG, Sader HS, Streit JM, Castanheira M, et al
    Activity of Oritavancin Against Gram-positive Pathogens Causing Bloodstream Infections in the United States Over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0166721. doi: 10.1128/AAC.01667.
    PubMed     Abstract available


  227. VOGENSEN VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, et al
    Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0182921. doi: 10.1128/AAC.01829.
    PubMed     Abstract available


  228. WEI J, Tong K, Wang H, Wen Y, et al
    Intra-articular vancomycin for the prophylaxis of periprosthetic joint infection caused by methicillin-resistant S. aureus after total knee arthroplasty in a rat model: the dosage, efficacy, and safety.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0164121. doi: 10.1128/AAC.01641.
    PubMed     Abstract available


  229. LEE YL, Ko WC, Hsueh PR
    Geographic Patterns of Carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015-2019.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0200021. doi: 10.1128/AAC.02000.
    PubMed     Abstract available


  230. CRANDON JL, Kuti JL, Nicolau DP
    Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model".
    Antimicrob Agents Chemother. 2021;65:e0187821.
    PubMed    


  231. REITZEL RA, Rosenblatt J, Gerges BZ, Vargas-Cruz N, et al
    Erratum for Reitzel et al., "Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms".
    Antimicrob Agents Chemother. 2021;65:e0198621.
    PubMed    


  232. NEWMAN LM, Kankam M, Nakamura A, Conrad T, et al
    Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
    Antimicrob Agents Chemother. 2021;65:e0129221.
    PubMed     Abstract available


  233. JOUSSET AB, Oueslati S, Emeraud C, Bonnin RA, et al
    KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
    Antimicrob Agents Chemother. 2021;65:e0116021.
    PubMed     Abstract available


  234. FIGUEIREDO ABC, Fonseca FL, Kuczera D, Conte FP, et al
    Monoclonal Antibodies against Cell Wall Chitooligomers as Accessory Tools for the Control of Cryptococcosis.
    Antimicrob Agents Chemother. 2021;65:e0118121.
    PubMed     Abstract available


  235. KERKEZ I, Tulkens PM, Tenson T, Van Bambeke F, et al
    Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.
    Antimicrob Agents Chemother. 2021;65:e0146821.
    PubMed     Abstract available


  236. MUHLEN S, Zapol'skii VA, Bilitewski U, Dersch P, et al
    Identification of Translocation Inhibitors Targeting the Type III Secretion System of Enteropathogenic Escherichia coli.
    Antimicrob Agents Chemother. 2021;65:e0095821.
    PubMed     Abstract available


  237. VANSCOY BD, Lakota EA, Conde H, Fikes S, et al
    Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems.
    Antimicrob Agents Chemother. 2021;65:e0012221.
    PubMed     Abstract available


  238. PEYRUSSON F, Whelan AO, Hartley MG, Norville IH, et al
    Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells.
    Antimicrob Agents Chemother. 2021;65:e0106121.
    PubMed     Abstract available


  239. KELLY MC, Yeager SD, Shorman MA, Wright LR, et al
    Incidence and Predictors of Gram-Negative Bacilli in Hospitalized People Who Inject Drugs with Injection Drug Use-Attributable Infections.
    Antimicrob Agents Chemother. 2021;65:e0092521.
    PubMed     Abstract available


  240. SORAYAH R, Moraski GC, Barkan D, Pethe K, et al
    The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021;65:e0096421.
    PubMed     Abstract available


  241. MARTINS O, Lee J, Kaushik A, Ammerman NC, et al
    In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021;65:e0154521.
    PubMed     Abstract available


  242. LI D, Sabato PE, Guiastrennec B, Ouerdani A, et al
    Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Antimicrob Agents Chemother. 2021;65:e0089521.
    PubMed     Abstract available


  243. SINGULANI JL, Oliveira LT, Ramos MD, Fregonezi NF, et al
    The Antimicrobial Peptide MK58911-NH2 Acts on Planktonic, Biofilm, and Intramacrophage Cells of Cryptococcus neoformans.
    Antimicrob Agents Chemother. 2021;65:e0090421.
    PubMed     Abstract available


  244. SHARMA D, Paul RA, Rudramurthy SM, Kashyap N, et al
    Impact of FKS1 genotype on echinocandin in-vitro susceptibility in Candida auris and in-vivo response in a murine model of infection.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0165221. doi: 10.1128/AAC.01652.
    PubMed     Abstract available


  245. NIIMI M, Niimi K, Tanabe K, Cannon RD, et al
    Inhibitor Resistant Mutants Give Important Insights into Candida albicans ABC Transporter Cdr1 Substrate Specificity and Help Elucidate Efflux Pump Inhibition.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0174821. doi: 10.1128/AAC.01748.
    PubMed     Abstract available


  246. YAMAMURO R, Kimura M, Asano-Mori Y, Abe M, et al
    Clinical and microbiological characteristics of proven invasive aspergillosis due to rare/cryptic species in allogeneic hematopoietic stem cell transplant recipients.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0163021. doi: 10.1128/AAC.01630.
    PubMed     Abstract available


  247. YU JF, Xu JT, Yang SS, Gao MN, et al
    Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0146521. doi: 10.1128/AAC.01465.
    PubMed     Abstract available


  248. RIVAS L, Alcalde-Rico M, Martinez JR, Moreno V, et al
    Real-world Performance of Susceptibility Testing for Ceftolozane/Tazobactam Against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0165721. doi: 10.1128/AAC.01657.
    PubMed     Abstract available


  249. PHAN MD, Peters KM, Alvarez Fraga L, Wallis SC, et al
    Plasmid-mediated ciprofloxacin resistance imparts a selective advantage on Escherichia coli ST131.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0214621. doi: 10.1128/AAC.02146.
    PubMed     Abstract available


  250. LIAO YS, Chen BH, Teng RH, Wang YW, et al
    Antimicrobial resistance in Campylobacter coli and Campylobacter jejuni from human campylobacteriosis in Taiwan, 2016-2019.
    Antimicrob Agents Chemother. 2021 Nov 8:AAC0173621. doi: 10.1128/AAC.01736.
    PubMed     Abstract available


  251. MORRISETTE T, Lev KL, Canfield GS, Duerkop BA, et al
    Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin Against Daptomycin-Nonsusceptible Enterococcus faecium.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0162321. doi: 10.1128/AAC.01623.
    PubMed     Abstract available


  252. KARAU MJ, Schmidt-Malan SM, Cunningham SA, Mandrekar JN, et al
    Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0170321. doi: 10.1128/AAC.01703.
    PubMed     Abstract available


    October 2021
  253. HERREN SC, Huemer M, Acevedo CT, Gomez-Mejia A, et al
    Assessing antibiotic tolerance of Staphylococcus aureus derived directly from patients by the Replica Plating Tolerance Isolation System - REPTIS.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0096721. doi: 10.1128/AAC.00967.
    PubMed     Abstract available


  254. ANAHTAR MN, Bramante JT, Xu J, Desrosiers LA, et al
    Prediction of antimicrobial resistance in clinical Enterococcus faecium isolates using a rules-based analysis of whole genome sequences.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0119621. doi: 10.1128/AAC.01196.
    PubMed     Abstract available


  255. BUTCHER MC, Brown JL, Hansom D, Wilson-Van Os R, et al
    Antifungal loaded calcium sulfate beads as a potential therapeutic in combating Candida auris.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0171321. doi: 10.1128/AAC.01713.
    PubMed     Abstract available


  256. MISHRA NN, Lew C, Abdelhady W, Lapitan CK, et al
    Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant S. aureus: In vitro, Ex vivo and In vivo Metrics.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164921. doi: 10.1128/AAC.01649.
    PubMed     Abstract available


  257. DEMCZUK W, Martin I, Griffith A, Lefebvre B, et al
    Linear regression equations to predict beta-lactam, macrolide, lincosamide and fluoroquinolone minimum inhibitory concentrations from molecular antimicrobial resistance determinants in Streptococcus pneumoniae.
    Antimicrob Agents Chemother. 2021 Oct 18:AAC0137021. doi: 10.1128/AAC.01370.
    PubMed     Abstract available


  258. BAKLOUTI S, Marolleau S, Chavanet P, Bonnet E, et al
    Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections".
    Antimicrob Agents Chemother. 2021 Oct 18:AAC0149321. doi: 10.1128/AAC.01493.
    PubMed     Abstract available


  259. CAFLISCH KM, Patel R
    Phage Activity Against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.
    Antimicrob Agents Chemother. 2021 Oct 18:AAC0187921. doi: 10.1128/AAC.01879.
    PubMed     Abstract available


  260. JIANG S, Zhuang H, Zhu F, Wei X, et al
    The role of mprF mutations in "see-saw effect" of Daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates.
    Antimicrob Agents Chemother. 2021 Oct 18:AAC0129521. doi: 10.1128/AAC.01295.
    PubMed     Abstract available


  261. BAGHDADI JD, Coffey KC, Adediran T, Goodman KE, et al
    Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
    Antimicrob Agents Chemother. 2021;65:e0134121.
    PubMed     Abstract available


  262. SHORTRIDGE D, Arends SJR, Streit JM, Castanheira M, et al
    Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.
    Antimicrob Agents Chemother. 2021;65:e0126421.
    PubMed     Abstract available


  263. TALLEY AK, Thurston A, Moore G, Gupta VK, et al
    First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.
    Antimicrob Agents Chemother. 2021;65:e0120821.
    PubMed     Abstract available


  264. FONTANA H, Cardoso B, Esposito F, de Lima AV, et al
    Small IncQ1 Plasmid Encoding KPC-2 Expands to Invasive Nontyphoidal Salmonella.
    Antimicrob Agents Chemother. 2021;65:e0155221.
    PubMed    


  265. GUO Q, Xu L, Tan F, Zhang Y, et al
    A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0088921.
    PubMed     Abstract available


  266. KOMM O, Almeida DV, Converse PJ, Omansen TF, et al
    Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
    Antimicrob Agents Chemother. 2021;65:e0141821.
    PubMed     Abstract available


  267. BANERJEE R, Cunningham SA, Beisken S, Posch AE, et al
    Core Genome Multilocus Sequence Typing and Prediction of Antimicrobial Susceptibility Using Whole-Genome Sequences of Escherichia coli Bloodstream Infection Isolates.
    Antimicrob Agents Chemother. 2021;65:e0113921.
    PubMed     Abstract available


  268. RUBINO CM, Flanagan S
    Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
    Antimicrob Agents Chemother. 2021;65:e0084221.
    PubMed     Abstract available


  269. LOVEY A, Krel M, Borchardt A, Brady T, et al
    Development of Novel Immunoprophylactic Agents against Multidrug-Resistant Gram-Negative Bacterial Infections.
    Antimicrob Agents Chemother. 2021;65:e0098521.
    PubMed     Abstract available


  270. STOTT KE, Le T, Nguyen T, Whalley S, et al
    Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.
    Antimicrob Agents Chemother. 2021;65:e0063621.
    PubMed     Abstract available


  271. CLAY KA, Hartley MG, Armstrong S, Bewley KR, et al
    Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever.
    Antimicrob Agents Chemother. 2021;65:e0067321.
    PubMed     Abstract available


  272. ZAIDAN N, Hornak JP, Reynoso D
    Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.
    Antimicrob Agents Chemother. 2021;65:e0092421.
    PubMed     Abstract available


  273. CUBRIA MB, Vega LA, Shropshire WC, Sanson MA, et al
    Population genomics reveals distinct temporal association with the emergence of ST1 serotype V Group B Streptococcus and macrolide resistance in North America.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0071421. doi: 10.1128/AAC.00714.
    PubMed     Abstract available


  274. WILLIAMSON B, Wilk A, Guerrero KD, Mikulski TD, et al
    Impact of Erg11 amino acid substitutions identified in Candida auris clade III isolates on triazole drug susceptibility.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0162421. doi: 10.1128/AAC.01624.
    PubMed     Abstract available


  275. EVERT BJ, Slesarenko VA, Punnasseril JMJ, Taha, et al
    Self-inhibitory peptides targeting the Neisseria gonorrhoeae MtrCDE efflux pump increase antibiotic susceptibility.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0154221. doi: 10.1128/AAC.01542.
    PubMed     Abstract available


  276. GANAPATHY US, Del Rio RG, Cacho-Izquierdo M, Ortega F, et al
    A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0151421. doi: 10.1128/AAC.01514.
    PubMed     Abstract available


  277. JACQUELINE C, Caillon J, Meyer O, Dailly E, et al
    Efficacy of Nano-Encapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus (MRSA) Bone and Joint Infection Model.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0076821. doi: 10.1128/AAC.00768.
    PubMed     Abstract available


  278. RADTKE KK, Ernest JP, Zhang N, Ammerman NC, et al
    Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling study.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705.
    PubMed     Abstract available


  279. IKEDA T, Suzuki R, Jin W, Wachino JI, et al
    Isolation of Group A Streptococci with Reduced In Vitro beta-Lactam Susceptibility Harboring Amino Acid Substitutions in Penicillin-Binding Proteins in Japan.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0148221. doi: 10.1128/AAC.01482.
    PubMed     Abstract available


    September 2021
  280. DIAZ-GARCIA J, Mesquida A, Gomez A, Machado M, et al
    Antifungal susceptibility testing identifies the abdominal cavity as a source of Candida glabrata resistant isolates.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0124921. doi: 10.1128/AAC.01249.
    PubMed     Abstract available


  281. ALMEIDA D, Converse PJ, Li SY, Upton AM, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0141221. doi: 10.1128/AAC.01412.
    PubMed     Abstract available


  282. INGLE DJ, Andersson P, Valcanis M, Wilmot M, et al
    Genomic epidemiology and antimicrobial resistance mechanisms of imported typhoid in Australia.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0120021. doi: 10.1128/AAC.01200.
    PubMed     Abstract available


    August 2021
  283. HOWARD-ANDERSON J, van Duin D
    Uncertainty in evaluating treatment outcomes in carbapenem-resistant Acinetobacter baumannii infections.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0142421. doi: 10.1128/AAC.01424.
    PubMed     Abstract available


  284. MUKHERJEE S, Blankenship HM, Rodrigues JA, Mosci RE, et al
    Antibiotic susceptibility profiles and frequency of resistance genes in clinical Shiga toxin-producing Escherichia coli isolates from Michigan over a 14-year period.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0118921. doi: 10.1128/AAC.01189.
    PubMed     Abstract available


  285. GILL CM, Aktathorn E, Alfouzan W, Bourassa L, et al
    Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.
    Antimicrob Agents Chemother. 2021 Aug 16:AAC0120421. doi: 10.1128/AAC.01204.
    PubMed     Abstract available


  286. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    PubMed     Abstract available


  287. GUTIERREZ-GUTIERREZ B, Perez-Nadales E, Perez-Galera S, Fernandez-Ruiz M, et al
    Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0110221. doi: 10.1128/AAC.01102.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: